Changed Date for the Annual General Meeting and Notice to Extraordinary General Meeting of Karo Bio AB
3/23/2012 6:22:04 AM
HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Karo Bio AB (publ).(STO:KARO):
According to the previous press release of 14 February 2012, Karo Bio has discontinued the clinical phase III-project with the lipid-lowering drug eprotirome and decided to terminate the project. The decision changes the conditions for the company’s continued direction. In order to give the Board of Directors and the executive management the opportunity for a new planning and renewed description of the business, the Board of Directors today has decided to postpone Karo Bio’s annual general meeting from 27 April 2012 to 12 June 2012. Notice will be issued no later than four weeks before the general meeting. The annual report of 2011 is expected to be made public no later than on May 22 2012.